Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the effectiveness of the study drug, ACTH
Gel in people diagnosed with dermatomyositis a disease that causes muscle weakness and is
associated with a rash (DM) or polymyositis (PM) a disease that causes muscle weakness
without a rash. The study doctors want to evaluate whether ACTH Gel will improve the symptoms
of this disease. This drug is approved by the Food and Drug Administration (FDA) for
dermatomyositis (DM) and polymyositis (PM). ACTH gel has been an FDA-approved treatment for
myositis since 1952, and in 2010 the FDA retained PM and DM as diseases approved for ACTH gel
use.